<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03393884</url>
  </required_header>
  <id_info>
    <org_study_id>201-17-201</org_study_id>
    <nct_id>NCT03393884</nct_id>
  </id_info>
  <brief_title>Study of GEN-1 With NACT for Treatment of Ovarian Cancer (OVATION 2)</brief_title>
  <acronym>OVATION 2</acronym>
  <official_title>A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celsion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celsion</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open label, multicenter trial to evaluate the safety, dosing, efficacy&#xD;
      and biological activity of intraperitoneal GEN-1 plus NACT compared to NACT alone.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 5, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>The primary analysis for PFS will be conducted after at least 80 events have been observed or after all patients have been followed for at least 16 months, whichever is later.</time_frame>
    <description>The primary objective of the study is to evaluate safety and compare progression free survival between subjects receiving neoadjuvant chemotherapy (NACT) plus GEN-1 versus standard NACT.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Epithelial Ovarian Cancer</condition>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Primary Peritoneal Cancer</condition>
  <arm_group>
    <arm_group_label>NACT + GEN-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The NACT regimen will be paclitaxel 175 mg/m2 IV over 3 hours followed by carboplatin AUC 6 IV over 1 hour on Day 1. This will be repeated every 3 weeks for 6 cycles. GEN-1 100 mg/m2 IP will be administered on Days 8 and 15 of the first NACT cycle and then on Days 1, 8, and 15 of the subsequent 21 day NACT cycles for a total of 17 treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NACT Alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The NACT regimen will be paclitaxel 175 mg/m2 IV over 3 hours followed by carboplatin AUC 6 IV over 1 hour on Day 1. This will be repeated every 3 weeks for 6 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GEN-1</intervention_name>
    <description>IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer</description>
    <arm_group_label>NACT + GEN-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>AUC 6 IV over 1 hour on Day 1 of each cycle</description>
    <arm_group_label>NACT + GEN-1</arm_group_label>
    <arm_group_label>NACT Alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>175 mg/m2 IV over 3 hours on Day 1 of each cycle</description>
    <arm_group_label>NACT + GEN-1</arm_group_label>
    <arm_group_label>NACT Alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must have suspected histologic diagnosis of epithelial ovarian, fallopian&#xD;
             tube, or primary peritoneal carcinoma per pre-treatment biopsies by laparoscopy, or&#xD;
             interventional radiology or CT guided core biopsy. Histologic documentation of the&#xD;
             original primary tumor is required via the pathology report.&#xD;
&#xD;
          2. Patients must have an International Federation of Gynecology and Obstetrics (FIGO) of&#xD;
             III or IV.&#xD;
&#xD;
          3. Patients with the following histologic epithelial cell types are eligible: High grade&#xD;
             serous adenocarcinoma, endometrioid adenocarcinoma, undifferentiated carcinoma, clear&#xD;
             cell adenocarcinoma, mixed epithelial carcinoma, or adenocarcinoma not otherwise&#xD;
             specified (N.O.S.).&#xD;
&#xD;
          4. Patients must have adequate:&#xD;
&#xD;
               1. Bone marrow function: Absolute neutrophil count (ANC) greater than or equal to&#xD;
                  1,500/mcl. This ANC cannot have been induced or supported by granulocyte colony&#xD;
                  stimulating factors. Platelets greater than or equal to 100,000/mcl.&#xD;
&#xD;
               2. Renal function: Creatinine ≤1.5 x institutional upper limit normal (ULN).&#xD;
&#xD;
               3. Hepatic function: Bilirubin ≤ 1.5 x ULN. SGOT (AST) and SGPT (ALT) ≤ 3.0 x ULN&#xD;
                  and alkaline phosphatase ≤ 2.5 x ULN.&#xD;
&#xD;
               4. Neurologic function: Neuropathy (sensory and motor) less than or equal to Grade&#xD;
                  1.&#xD;
&#xD;
          5. Patients should be free of active infection requiring parenteral antibiotics or a&#xD;
             serious uncontrolled medical illness or disorder within four weeks of study entry.&#xD;
&#xD;
          6. Any hormonal therapy directed at the malignant tumor must be discontinued at least one&#xD;
             week prior to the first treatment. Continuation of hormone replacement therapy is&#xD;
             permitted.&#xD;
&#xD;
          7. Patients must have a performance status score of 0, 1 or 2 by Eastern Cooperative&#xD;
             Group (ECOG) criteria.&#xD;
&#xD;
          8. Patients of childbearing potential must have a negative serum pregnancy test within 14&#xD;
             days prior to initiation of protocol therapy and be practicing an effective form of&#xD;
             contraception. If applicable, patients must discontinue breastfeeding prior to study&#xD;
             entry.&#xD;
&#xD;
          9. Patients must have satisfactory results for the baseline laboratory analyses and&#xD;
             diagnostic procedures as specified in the protocol.&#xD;
&#xD;
         10. Patients must have signed an IRB-approved informed consent and authorization&#xD;
             permitting release of personal health information.&#xD;
&#xD;
         11. Patients must be at least 18 years old.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have received prior treatment with GEN-1.&#xD;
&#xD;
          2. History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to GEN-1 or other agents used in this study.&#xD;
&#xD;
          3. Patients who have received oral or parenteral corticosteroids within 2 weeks of study&#xD;
             entry or who have a clinical requirement for ongoing systemic immunosuppressive&#xD;
             therapy such as chronic steroid use not related to chemotherapy administration.&#xD;
&#xD;
          4. Patients receiving treatment for active autoimmune disease. &quot;Active&quot; refers to any&#xD;
             condition currently requiring therapy. Examples of autoimmune disease include systemic&#xD;
             lupus erythematosus, multiple sclerosis, inflammatory bowel disease and rheumatoid&#xD;
             arthritis.&#xD;
&#xD;
          5. Patients with other invasive malignancies, with the exception of non-melanoma skin&#xD;
             cancer and other specific malignancies as noted in the protocol are excluded if there&#xD;
             is any evidence of other malignancy being present within the last three years.&#xD;
             Patients are also excluded if their previous cancer treatment contraindicates this&#xD;
             protocol therapy.&#xD;
&#xD;
          6. Patients who have received prior radiotherapy to any portion of the abdominal cavity&#xD;
             or pelvis are excluded. Prior radiation for localized cancer of the breast, head and&#xD;
             neck, or skin is permitted, provided that it was completed more than three years prior&#xD;
             to registration, and the patient remains free of recurrent or metastatic disease.&#xD;
&#xD;
          7. Patients who have received prior chemotherapy for any abdominal or pelvic tumor are&#xD;
             excluded. Patients may have received prior adjuvant chemotherapy for localized breast&#xD;
             cancer, provided that it was completed more than three years prior to registration,&#xD;
             and that the patient remains free of recurrent or metastatic disease.&#xD;
&#xD;
          8. Patients with known active hepatitis.&#xD;
&#xD;
          9. Patients with concurrent severe medical problems unrelated to the malignancy that&#xD;
             would significantly limit full compliance with the study or expose the patient to&#xD;
             extreme risk or decreased life expectancy.&#xD;
&#xD;
         10. Patients of childbearing potential, not practicing adequate contraception, patients&#xD;
             who are pregnant, or patients who are breastfeeding are not eligible for this trial.&#xD;
&#xD;
         11. Patients with history or evidence upon physical examination of CNS disease, including&#xD;
             primary brain tumor, seizures not controlled with standard medical therapy, any brain&#xD;
             metastases, or history of cerebrovascular accident (CVA, stroke), transient ischemic&#xD;
             attack (TIA) or subarachnoid hemorrhage within six months of the first date of&#xD;
             treatment on this study.&#xD;
&#xD;
         12. Patients with any condition/anomaly that would interfere with the appropriate&#xD;
             placement of the IP catheter for study drug administration including: abdominal&#xD;
             surgery within 4 weeks of study entry (for reasons other than IP port placement),&#xD;
             intestinal dysfunction, or suspected extensive adhesions from prior history or finding&#xD;
             at laparoscopy.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Premal H. Thaker, M.D</last_name>
    <role>Study Chair</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicholas Borys, M.D.</last_name>
    <phone>609-896-9100</phone>
    <email>nborys@celsion.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lauren Musso</last_name>
    <phone>609-896-9100</phone>
    <email>lmusso@celsion.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terry Sirles</last_name>
      <email>tsirles@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Charles Leath III, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mitchell Cancer Institute (University of South Alabama)</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanie Broemmelsiek, BSN, RN</last_name>
      <email>jbroemmelsiek@health.southalabama.edu</email>
    </contact>
    <investigator>
      <last_name>Rodney Rocconi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California - San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0698</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Aguilar</last_name>
      <email>k1aguilar@health.ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Michael McHale, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gynecologic Oncology Associates (Hoag Hospital)</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Navarrete</last_name>
      <email>ana.navarrete@hoag.org</email>
    </contact>
    <investigator>
      <last_name>Alberto Mendivil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Innovative Clinical Research</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirsten Bettino</last_name>
      <email>kbettino@airesearch.us</email>
    </contact>
    <investigator>
      <last_name>Richy Agajanian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Center for Gynecologic Oncology</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Advent Health</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Leblanc</last_name>
      <email>Jane.Leblanc@AdventHealth.com</email>
    </contact>
    <investigator>
      <last_name>Robert Holloway, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Women's Care Florida</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Penny Thompson</last_name>
      <email>pethompson@womenscarefl.com</email>
    </contact>
    <investigator>
      <last_name>Megan Indermaur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ha Nguyen</last_name>
      <email>hnguyen54@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Amy Bregar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Drake</last_name>
      <email>sarahdrake@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Lindsay Kuroki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Billings Clinic</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson at Cooper</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annette Foti</last_name>
      <email>foti-annette@cooperhealth.edu</email>
    </contact>
    <investigator>
      <last_name>David Warshal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aretha DiSalvo</last_name>
      <email>aretha.disalvo@hmhn.org</email>
    </contact>
    <investigator>
      <last_name>Donna McNamara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monter Cancer Center</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Agnes Templeton</last_name>
      <email>mtempleton@northwell.edu</email>
    </contact>
    <investigator>
      <last_name>Veena John, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Langone</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malcolm DeLara</last_name>
      <email>malcolm.delara@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Bhavana Pothuri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stephenson Cancer Center - Oklahoma University</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kortni Gentry</last_name>
      <email>kortni-gentry@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Debra Richardson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nora Auston</last_name>
      <email>nora.auston@providence.org</email>
    </contact>
    <investigator>
      <last_name>Christopher Darus, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanford Health</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Johnson</last_name>
      <email>Ashley.Johnson9@SanfordHealth.org</email>
    </contact>
    <investigator>
      <last_name>Maria Bell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chattanooga Women's Health</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Donelson</last_name>
      <email>Kimberly.Donelson@erlanger.org</email>
    </contact>
    <investigator>
      <last_name>Stephen DePasquale, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The West Clinic</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madison Smith</last_name>
      <email>Madsmith@WESTCLINIC.com</email>
    </contact>
    <investigator>
      <last_name>Adam Elnaggar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Health Care</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Flores</last_name>
      <email>claudia.flores@providence.org</email>
    </contact>
    <investigator>
      <last_name>Melanie Bergman, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiana Christian</last_name>
      <email>qchristian@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>William Bradley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maimouna Barry</last_name>
      <email>maimouna.barry.ccomtl@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Susie Lau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHUM</name>
      <address>
        <city>Montréal</city>
        <zip>H2X 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adeline Hamon</last_name>
      <email>adeline.hamon.chum@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Diane Provencher, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 3, 2018</study_first_submitted>
  <study_first_submitted_qc>January 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2018</study_first_posted>
  <last_update_submitted>June 25, 2021</last_update_submitted>
  <last_update_submitted_qc>June 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

